Interview with the Innovators

Supported by BridgeBio

Complexities of Transthyretin Amyloid Disposition

Joel N Buxbaum, MD
Molecular Medicine
The Scripps Research Institute
Chief Medical Officer
Protego Biopharma
Joel N. Buxbaum, MD, Professor Emeritus, Molecular Medicine, The Scripps Research Institute, and Chief Medical Officer (consulting), Protego Biopharma, explores the mechanisms of organ damage in TTR amyloidosis (ATTR). This important information focuses on the biophysical and biochemical underpinnings of misfolded transthyretin (TTR) leading to tissue dysfunction in this disease.

Related Items

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: